Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and p…

Biotechnology

US, Wilmington [HQ]

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Incyte Corporation's gradings, price targets and earnings estimates. None

Earnings
Grading & Price

Reported

Past Estimate Consensus

Future Estimate Consensus

EPS Revenue EBITDA EBIT SGA

All monetary values are presented in USD ($). E stands for Estimate.

Download

FY	EPS		Revenue [mil.]		Profit [mil.]		EBITDA [mil.]		EBIT [mil.]		Expenses · SGA [mil.]
		E		E		E		E		E		E
2014	-0.5600	-0.045	354	151	-83	1,491	-14	23	-16	20	109	38
2015	-0.2900	-0.190	511	735	-48	19	-1	84	-4	56	165	281
2016	0.0400	0.620	753	1,104	6	1,081	57	170	50	970	196	280
2017	0.5500	-1.280	1,105	1,520	104	-251	166	-212	162	-182	303	247
2018	-1.5300	0.500	1,536	1,787	-313	91	-218	175	-236	94	366	605
2019	0.5200	1.885	1,881	2,156	109	291	187	357	155	264	434	305
2020	2.0800	-1.314	2,158	2,537	446	-4,063	473	-3,799	421	-3,718	468	1,067
2021	-1.3600	2.584	2,666	2,924	-295	1,333	-217	601	-240	538	516	809
2022	4.3000	1.760	2,986	3,338	948	1,448	611	688	600	693	739	1,014
2023	1.5300	3.599	3,394	3,688	340	597	631	756	591	762	1,002	1,115
2024	2.6700	1.266	3,695	4,203	597	286	904	650	649	560	1,161	1,066
2025	-	5.919	-	4,631	-	1,341	-	716	-	618	-	1,174
2026	-	2.F12X/td>	-	2.F12X/td>	-	2.F12X/td>	-	2.F121/td>	-	2.F121	-	2.F121
2027	-	1.F13X/td>	-	1.F13X/td>	-	1.F13X/td>	-	1.F131/td>	-	1.F131	-	1.F131
2028	-	0.F14X/td>	-	0.F14X/td>	-	0.F14X/td>	-	0.F141/td>	-	0.F141	-	0.F141